TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05351762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab Combined With Neoadjuvant Chemotherapy
Description: The study arm received nimotuzumab (400mg, every three weeks, for 2 weeks) combined with TPF chemotherapy
Study: NCT06660940

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Keluoxin Capsule Simulants
Description: Treatment period (52 weeks):Keluoxin Capsule Simulants, 4 capsules/time, swallow with warm water after meals, 3 times/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: 1. Lead-in period (2-4 weeks): Irbesartan 75-300mg/d, QD;~2. Treatment period (52 weeks): Irbesartan 75-300mg/d, QD
Study: NCT05647954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008 + TACE
Description: HX008 Subjects receive HX008 200 mg intravenous (IV) ,day1,every 3 weeks (Q3W) Procedure: TACE cisplatin 75 mg/sqm, day1, every 6 weeks; fotemustine 100 mg/sqm, day2, every 6 weeks; lipiodol is usually 5-10 ml (According to the location and number of lesions).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide + TACE
Description: Temozolomide Subjects receive Temozolomide 200 mg/sqm intravenous (IV),day1-5, every 3 weeks (Q3W)~Procedure: TACE :~cisplatin 75 mg/sqm, day1, every 6 weeks; fotemustine 100 mg/sqm, day2, every 6 weeks; lipiodol is usually 5-10 ml (According to the location and number of lesions).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Subjects receive Pembrolizumab 2 mg/kg intravenous (IV),day1, every 3 weeks (Q3W)
Study: NCT04804566

Intervention type: OTHER
Intervention: This is a non-interventional study
Description: This is a non-interventional study

Intervention type: OTHER
Intervention: This is a non-interventional study
Description: This is a non-interventional study

Intervention type: OTHER
Intervention: This is a non-interventional study
Description: This is a non-interventional study

Intervention type: OTHER
Intervention: This is a non-interventional study
Description: This is a non-interventional study
Study: NCT04767373

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clesrovimab
Description: Clesrovimab solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (0.9% sodium chloride \[NaCL\]) solution
Study: NCT06408025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Syrenity App
Description: Currently, the Syrenity App has two active interventions. One is an exposure-based intervention called Face your fears. Another is an intervention based on behavioral activation called Get better. The app also provides self-report questionnaires for tracking mood along with psychoeducation on a variety of topics relevant to mental health.
Study: NCT06660940

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Irbesartan
Description: 1. Lead-in period (2-4 weeks): Irbesartan 75-300mg/d, QD;~2. Treatment period (52 weeks): Irbesartan 75-300mg/d, QD
Study: NCT06661291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pip Care Digital Health Platform
Description: Pip Care Digital Health Platform is a smartphone application granting access to a health coach who will assist the patient in completing a health intake, creating personalized perioperative care plans, and meets regularly with the patient to encourage goal accomplishments and supports healthy surgical recovery.
Study: NCT06238050

Intervention type: PROCEDURE
Intervention: introduction of oxygen therapy or not
Description: During hospitalisation, surgeon decides if patient needs and will have an oxygen therapy during this hospitalisation and at home.
Study: NCT06635538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa (CFA) 150 mcg + Clomiphene Citrate (CC) 100 mg/day from D1
Description: On day 2 or 3 of the menstrual cycle or after 5 days of pill-free interval, a single injection of 150 mcg of CFA (Stimulation Day 1) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate (CC) 100 mg/day from D1
Description: On day 2 or 3 of the menstrual cycle or after 5 days of pill-free interval, the patients will start oral administration of Clomiphene Citrate 100/day continuing up to and including the day of ovulation triggering

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Monitoring cycle
Description: Scan controls and blood exams will be performed on stimulation days 1, 6, 8, 10 and, according to clinical needs, until trigger day.
Study: NCT06116929

Intervention type: OTHER
Group type: OTHER
Intervention: Morphological and functional magnetic resonance imaging (MRI)
Description: Patients will undergo 3 morphological and functional MRI scans (during rest and activity) on the 3T MRI scanner at St Philibert Hospital (Lille, France) at 0 (M0), 6 (M6) and 12 (M12) months.~The controls will perform a single functional MRI on the 3T MRI.
Study: NCT06661291

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Protocol
Description: Subjects in this intervention group will receive routine, standard of care throughout their surgery and hospital stay as determined by their acting clinical care team.
Study: NCT06658418

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: dexmedetomidine combined with bupivacaine versus dexamethasone combined with bupivacaine for ultrasound-guided ESPB for postoperative pain control in patients scheduled for abdominal surgeries.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: dexmedetomidine combined with bupivacaine versus dexamethasone combined with bupivacaine for ultrasound-guided ESPB for postoperative pain control in patients scheduled for abdominal surgeries.
Study: NCT06659185

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The effects of placobo mouth rinsing on softball batting performance

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: The effects of placobo mouth rinsing on softball batting performance
Study: NCT06657872

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: water vapor therapy under general anesthesia
Description: Water vapor procedure will be performe under conscious intravenous sedation with anesthesia team

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: water vapor therapy under local anesthesia
Description: Water vapor procedure will be performe under local anethesia administrated with Schelin® catheter via the trans-urethral route : injection of 20cc of lidocaine 2% intra-prostatically via the schelin catheter at 4 injection points (3cc at 1h, 3cc at 11h, 7cc at 4h, and 7cc at 8h).
Study: NCT06660082

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental treatment: Head movements
Description: These are gaze stabilisation exercises under vHIT control, between post-operative days 1 to 6.~The patient sits facing a wall 2 metres away. The investigator places the vHIT device on the participant's head and ensures that it fits properly.~This is followed by an initial calibration phase (the patient must follow a laser dot with his eyes).~Then comes stimulation phase: the investigator, standing behind the patient, places his hands on the sides of the patient's lower jaw, which he is asked to clench. The investigator asks the subject to stare at a visual target on the wall in front of the patient. The investigator then performs a series of low-amplitude, high-speed head movements in the plane of the lateral canals and on the side of the vestibular deficit.~The patient is encouraged to resume fixation of the visual target as quickly as possible.~For each treatment session, patients should perform a minimum of 10 impulses and a maximum of 30 impulses on the deafferented side. Each

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment: only eye movements
Description: These are visually guided saccade exercises under vHIT device control but without head movements (saccade module), between post-operative days 1 to 6.~For this sham treatment, the modalities are identical to the experimental treatment session, up to the calibration phase described above.~For the stimulation phase, the investigator, standing behind the patient, places his hands on the sides of the patient's lower jaw, which he is asked to clench. The investigator asks the subject to stare at a visual target on the wall in front of the patient. The target then jumps horizontally to trigger visually guided saccades or slides horizontally to trigger an eye-tracking movement. The investigator stabilises the patient's head to prevent any head movement. The patient is encouraged to resume or maintain fixation of the visual target as quickly as possible.~A minimum of 5 horizontal saccade sequences and 5 horizontal eye-tracking sequences will be performed. Each training session lasts approxi
Study: NCT06660160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program supported by audiovisual media
Description: The intervention group will perform the group exercise protocol during HD sessions. The videos with the exercises will be broadcast on all televisions simultaneously, so that the volunteers perform the exercises along with the person in the video.~* The first level of difficulty includes 5 exercises for the lower limbs and 3 exercises for the upper limbs. One set of 10 repetitions will be performed for each exercise per session.~* The second level includes 3 exercises for the lower limbs and 2 exercises for the upper limbs. These consist of proprioceptive neuromuscular facilitation diagonals for both the lower and upper limbs. One set of 10 repetitions will be performed for each exercise, once per week, for 3 weeks.~* The third level includes 8 combined lower and upper limb exercises performed simultaneously. One set of 20 repetitions will be performed for each exercise.~Exercises will be performed 3 times per week over a 4-week period, for a total of 12 planned exercise sessions.
Study: NCT06660966

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: M TAPA block
Description: Grup M: The patients who underwent M-TAPA block were placed in the supine position. The right upper quadrant of the abdomen was cleaned with antiseptic solution. For the block procedure, 20-30 ml of 0.25% bupivacaine, 22G 8.5 cm stimuplex needle and 10-14 Hz high frequency USG were prepared for the procedure. The USG probe was determined in the costochondral area at the mid-clavicular line, and the internal and transversus abdominis muscles were determined. The needle was advanced with the in plane technique from cephalad to caudal, passing through the skin, subcutaneous, external and internal oblique muscles, respectively, and then over the transversus abdominis fascia. After the target was confirmed with 2 ml of saline, 0.3 mg / kg bupivacaine (20-30 ml) was administered.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP block group
Description: In Group E, patients who were to undergo ESP block were placed in the lateral position with the right side up. The T8-T10 dorsal region was cleaned appropriately with antiseptic solution. For the block procedure, 20-30cc %0.25 bupivacaine, 22G 8.5cm stimuplex needle and 10-14Hz high frequency USG were prepared for the procedure.~The USG probe is first determined in the sagittal direction, the spinous process of the T10 thoracic vertebra is then followed 1-2 cm above the transverse process, with the in plane technique, the skin, subcutaneous tissue and erector spina muscle are passed, the needle is touched to the transverse process and the target is confirmed with 2cc saline, then 20-30 cc (0.5 mg / kg bupivacaine) of local anesthetic is administered and the procedure is terminated.
Study: NCT06657963

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Opuntia ficus-indica Supplementation
Description: Participants are required to consume oral supplementation of OFi fine powder packaged in individual sachets (LifeGreenTM, LifeTree Asia, Selangor, Malaysia) at the dosage of 1500 mg once daily for 3 months.
Study: NCT06658158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive correction and stimulus control
Description: Cognitive correction:~a) correcting unrealistic sleep expectations; b) maintaining a natural sleep onset; c) avoiding worry about losing control oversleep; d) not associating nocturnal dreaming with adverse daytime consequences; e) avoiding feelings of frustration due to one night of poor sleep; f) developing tolerance to the impact of insomnia and avoiding compensatory behaviors.~Stimulus control:~1. Minimize wakefulness during time in bed and establish a positive association between sleepiness and the bed.~2. Use the bed only for sleep and sexual activities.~3. Go to bed only when feeling sleepy at night or at the designated sleep time.~4. If unable to fall asleep within approximately 20 minutes of being in bed, leave the bedroom, engage in relaxing activities, and return to bed when feeling sleepy. Repeat this process if unable to fall asleep within approximately 20 minutes.~5. Wake up at the same time every morning, including weekends.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene education
Description: 1. Sleep until feeling refreshed the next day.~2. Maintain regular exercise and eating habits, avoiding going to bed on an empty stomach.~3. Ensure a comfortable bedroom environment with suitable nighttime temperature, free from light and noise disturbances.~4. Avoid excessive consumption of beverages, alcohol, and smoking at night, and reduce caffeine intake.~5. Avoid bringing problems to bed and refrain from attempting to sleep.~6. Place the alarm clock under the bed or move it away from sight.~7. Avoid daytime napping.
Study: NCT06659913

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Session 1: Consist of high intensity interval training performed on spinning bikes. An exercise physiologist will supervise the participants to perform a light 10 min warm-up, followed by 4 min working periods (intervals) interspersed by 3 min active breaks. The intensity should be 85-95% of estimated peak heart rate, corresponding to approximately 16 on the Borg scale (17). There will be a maximum of 10 participants in each group, depending on how many patients who are recruited for each of the two inclusion periods.I In addition, participants are encouraged to participate in the physical education at school and encouraged to perform exercise during the weekend, either with their family or friends.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Session 1: Consist of high intensity interval training performed on spinning bikes. An exercise physiologist will supervise the participants to perform a light 10 min warm-up, followed by 4 min working periods (intervals) interspersed by 3 min active breaks. The intensity should be 85-95% of estimated peak heart rate, corresponding to approximately 16 on the Borg scale (17). There will be a maximum of 10 participants in each group, depending on how many patients who are recruited for each of the two inclusion periods.I In addition, participants are encouraged to participate in the physical education at school and encouraged to perform exercise during the weekend, either with their family or friends.
Study: NCT06661070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrolysis Percutaneous Therapeutic (EPTE)
Description: EPTE device (Ionclinics, Valencia, Spain)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrolysis Percutaneous Therapeutic (EPTE)
Description: EPTE device (Ionclinics, Valencia, Spain)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: A dry needle with size 0.30 × 40 (Agupunt, Barcelona, Spain)
Study: NCT06388148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical management
Description: Medical management includes IV thrombolysis, antiplatelet, and/or anticoagulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical management
Description: Medical management includes IV thrombolysis, antiplatelet, and/or anticoagulation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Description: Endovascular thrombectomy with stent-retriever, local aspiration, angioplasty, and/or stenting.
Study: NCT06116929

Intervention type: OTHER
Group type: OTHER
Intervention: Morphological and functional magnetic resonance imaging (MRI)
Description: Patients will undergo 3 morphological and functional MRI scans (during rest and activity) on the 3T MRI scanner at St Philibert Hospital (Lille, France) at 0 (M0), 6 (M6) and 12 (M12) months.~The controls will perform a single functional MRI on the 3T MRI.

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological assessment
Description: 3 neuropsychological assessments will be carried out at M0, M6 and M12, by the same neuropsychologist for all patients included.~Controls will undergo the same neuropsychological assessments, but only once.

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological assessment
Description: 3 neuropsychological assessments will be carried out at M0, M6 and M12, by the same neuropsychologist for all patients included.~Controls will undergo the same neuropsychological assessments, but only once.
Study: NCT05141539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation assessment software
Description: In phase 2, this software will be tested in occupational therapists, and head and neck cancer patients results for reliability and validity.~In phase 3, the experiment in the oropharyngeal dysphagia specialists results in content validity, the comparison between the developed software, and VFSS and FOIS results in criterion-related validity, and the experiment in head and neck cancer patients results in reliability.
Study: NCT05518994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus Bevacizumab
Description: 200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus Bevacizumab
Description: 200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks.
Study: NCT06386367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monastery-based health education by Buddhist monks
Description: During the three-month intervention from July to September 2022, a total of 18 health education sessions were conducted across the three intervention villages, with an average of 50 attendees per session, totaling 921 attendees across all sessions.
Study: NCT06001892

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tennessee Youth Prepared for Success
Description: both 5 day classroom interventions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tennessee Youth Prepared for Success
Description: both 5 day classroom interventions.
Study: NCT04725604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pH probe
Description: Patients who agree to take part will have a pH probe inserted into their injured limb. The pH probe will be attached to a pH monitor which will record pH data for up to a maximum of 72 hours (24 hours per probe). The surgical team will not have access to the pH data. During the time they are considered at risk for ACS, patients will be monitored in the routine way (using regular clinical assessment and pressure monitoring). If ACS is diagnosed in the routine way, then treatment (fasciotomy) will be offered as appropriate.
Study: NCT06179355

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manual astigmatic keratotomy
Description: manual astigmatic keratotomy using a diamond knife

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: femtosecond laser astigmatic keratotomy
Description: astigmatic keratotomy using femtosecond lase
Study: NCT04844450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-75220795
Description: JNJ-75220795 will be administered subcutaneously.
Study: NCT05038189

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gait parameters
Description: Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
Study: NCT04844450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-75220795
Description: JNJ-75220795 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously.
Study: NCT06258265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279 Placebo
Description: TAK-279 matching placebo capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279 Placebo
Description: TAK-279 matching placebo capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279 Placebo
Description: TAK-279 matching placebo capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin over-encapsulated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin over-encapsulated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Moxifloxacin matching placebo capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Moxifloxacin matching placebo capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Moxifloxacin matching placebo capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Moxifloxacin matching placebo capsule.
Study: NCT05038189

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spine posture
Description: Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.